Carriage Clearance of Emerging Highly Resistant Bacteria in Chronic Dialysis Patients
NCT04699682 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2023-04-14
Summary
The propias, and more recently the update of the recommendations relating to the control of the spread of bacteria highly resistant to emerging antibiotics issued by the High Council of Public Health (December 2019), recommend the implementation of measures to maintain the rate of Carbapenemase-producing Enterobacteriaceae (EPC) such as Klebsiella pneumoniae (K. pneumoniae) isolated from bacteremia in healthcare establishments in France at less than 1%, and that of Vancomycin Resistant Enterococcus (VRE) belonging to Enterococci Resistant to Glycopeptides (ERG) such as Enterococcus faecium isolated from bacteremia in health establishments in France at less than 1% also. At the same time, the prevalence of colonized patients is increasing. One of the recommended measures concerns the fight against cross transmission.
Due to the high technicality of the treatments, the risks of cross-transmission are very high and present at each stage of the dialysis procedure. Screening and isolation of patients colonized with emerging Highly Resistant Bacteria (BHRe) is essential to avoid their spread and the risk of infection with these germs.
Screening is done using rectal swabs. If the patient is found to be a carrier of BHRe, he should be isolated. Isolation is made more difficult in the hemodialysis room due to their architectural configuration, the organization of care and the chronicity of the patients. Patients have a monthly sample.
The isolation is allowed after obtaining six consecutive negative rectal swabs, the number of which has been arbitrarily defined. Indeed, the negativation of the samples does not confirm the disappearance of the carriage (that is to say the presence of BHRe), hence the need to repeat them. Persistence of colonization at a rate below the detection limit is possible. With for corollaries:
* Isolation which could be lifted more quickly in the event of real disappearance of the strain since the investigators know that a prolonged period of isolation can lead to a loss of opportunity for the patient and the investigators know its impact for the patient, on the operation of the service and its cost, with in particular the increase in withdrawals.
* Isolation lifted too early in the event of persistent carriage with risk of secondary transmission.
The interest of this study is to determine the clearance of the carriage of BHRe, i.e. their disappearance, in the chronic dialysis patient and to define, secondly, the factors associated with the prolonged carriage corresponding to the presence of bacteria for more than 3 months. , and elements of answer concerning the early disappearance of the EPC in the event of co-colonization by ERG and EPC. The follow-up of this carriage for 1 year will make it possible to evaluate the relapse corresponding to the reappearance of the bacteria previously identified, the recolonization corresponding to the acquisition of a new BHR, or the reinfection corresponding to an infection with a new highly resistant bacterium.
Conditions
- Chronic Kidney Diseases
- Dialysis
Interventions
- OTHER
-
Control
During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
- OTHER
-
BHR Case
During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below: \- stool samples taken at different times: * every 7 days during the first month (M1) * every 14 days for the following months until the end of the patient's participation (M2 to M12).
Sponsors & Collaborators
-
Fondation Hôpital Saint-Joseph
lead OTHER
Principal Investigators
-
Cecile BOURGAIN, MD · AURA Paris Plaisance
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-15
- Primary Completion
- 2024-01-14
- Completion
- 2025-03-14
Countries
- France
Study Locations
More Related Trials
-
Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments
NCT01703299 ·Status: COMPLETED
-
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
NCT02852902 ·Status: COMPLETED
-
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections
NCT06185153 ·Status: RECRUITING
-
Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
NCT03477084 ·Status: COMPLETED
-
Community-associated Highly-Resistant Enterobacterales
NCT03924934 ·Status: COMPLETED
-
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
NCT02709408 ·Status: COMPLETED
-
Digestive Colonisation by Highly Resistant Bacteria (CODBAHRE)
NCT04085380 ·Status: COMPLETED
-
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study
NCT01764490 ·Status: COMPLETED
-
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
NCT02482051 ·Status: COMPLETED
-
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
NCT03338738 ·Status: COMPLETED ·Phase: NA
-
Prognostic Factors of Escherichia Coli Bloodstream Infections: Severity Score and Therapeutic Implications
NCT02890901 ·Status: COMPLETED
-
Impact of Intestinal Microbiota on Uremic Toxins Productions
NCT04768309 ·Status: COMPLETED ·Phase: NA
-
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital
NCT06173440 ·Status: RECRUITING
-
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
NCT01820793 ·Status: TERMINATED ·Phase: NA
-
Deescalating Carbapenems in Hospital Setting
NCT02265445 ·Status: TERMINATED ·Phase: PHASE4
-
Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM
NCT05285046 ·Status: UNKNOWN
-
Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria
NCT04065750 ·Status: UNKNOWN
-
Prevalence of ESBL and CPE in French Nursing Homes
NCT03401242 ·Status: COMPLETED
-
Transmission of ESBL-producing Enterobacteriaceae
NCT03465683 ·Status: RECRUITING
-
Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae
NCT02005159 ·Status: COMPLETED
-
Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.
NCT03248999 ·Status: COMPLETED ·Phase: NA
-
Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region
NCT02803710 ·Status: UNKNOWN
-
Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital
NCT04577989 ·Status: COMPLETED
-
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital
NCT05798351 ·Status: RECRUITING
-
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
NCT01324726 ·Status: COMPLETED